Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

Keynote speakers to discuss regenerative medicine therapies at upcoming forum

What regenerative medicine therapies are being applied to patients today? What hurdles stand between stem cell therapies and real treatments in the clinic? Keynote speakers at the upcoming inaugural Translational Regenerative Medicine Forum will discuss these topics as well as provide an update on various national and regional stem cell initiatives.

16 Mar 2010

FDA approves Irvine Scientific's Vit Kit-Freeze and Vit Kit-Thaw for cryopreservation of all stages of embryos

Irvine Scientific, a pioneer in developing products specifically for the Assisted Reproductive Technology (ART) community, announced today that the U.S. Food and Drug Administration (FDA) has approved their products intended for vitrification of pronuclear (PN) zygotes through day 3 cleavage and blastocyst stage embryos within the fertility area.

16 Mar 2010

Houston scientists unveil new technique for growing 3-D cell cultures

The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.

16 Mar 2010

EHSI signs profit sharing deal with Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it locked down an option for a profit participation deal with biotech firm Celulas Genetica. Celulas Genetica works to develop new major medical solutions using adult stem cell research.

16 Mar 2010

ATS releases new clinical policy statement on CCHS

The American Thoracic Society has released a new official clinical policy statement on congenital central hypoventilation syndrome (CCHS), a disorder of respiratory and autonomic nervous system (ANS) regulation. The ANS regulates reflexive acts, including heart rate and blood pressure, digestion, body temperature and pain perception.

15 Mar 2010

UC Irvine researchers play leading role in genome sequencing of Hydra

UC Irvine researchers have played a leading role in the genome sequencing of Hydra, a freshwater polyp that has been a staple of biological research for 300 years.

15 Mar 2010

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

New micromanipulator for precise operations involving cochlear and middle ear implants

A team of engineers from the CEIT-IK4 technological centre and doctors from the University Hospital of Navarra have designed a new tool for operating on the inner ear with maximum precision, reducing the possibility of damage to the auditory function during the surgery. This is the first micromanipulator specifically for operations involving cochlear and middle ear implants, of which about a hundred are carried out in this hospital annually. Taking part in developing the new tool were four engineers from CEIT and five ear, nose and throat specialists from the University Hospital of Navarra.

12 Mar 2010

Researchers identify a novel source of adult stem cells: Foreign body-induced granulation tissue

In a pioneering new study published in the journal Translational Research, Dr. Jilpa Patel and her research group at Hektoen Institute of Medicine and Cook County Hospital in Chicago have isolated and characterized adult stem cells from granulation tissue in rats. A granulation tissue is a new regenerating tissue formed in response to an inert foreign body placed in the subcutaneous tissue.

11 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

Molecular master switch plays a key role in maturation process of brain cells

About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses.

11 Mar 2010

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.

11 Mar 2010

Researchers identify new treatment strategy for lymphoma

Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.

11 Mar 2010

Mayo Clinic to form new permanent professorship for cancer research

Mayo Clinic is forming a new permanent professorship to augment cancer research that will focus on finding new treatments and preventive measures to reduce the incidence of cancer.

11 Mar 2010

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.

10 Mar 2010